**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Valdis Ģībietis, Riga Stradiņš University, Pauls Stradiņš Clinical University Hospital, Riga, Latvia

**Main Body of the Abstract**
Introduction
Daratumumab, an anti-CD38 monoclonal antibody, has recently been approved by FDA and EMA for first-line treatment of systemic light chain (AL) amyloidosis in combination with cyclophosphamide, bortezomib and dexamethasone (Dara-CyBorD). In this case series we share our experience in treatment of AL amyloidosis with Dara-CyBorD.
Case series
From August 2022 to January 2024 overall 10 patients (6 female) with newly diagnosed AL amyloidosis received treatment with the Dara-CyBorD regimen. Age ranged from 44 to 74 years at the beginning of treatment (median 57 [IQR 53-62]). One patient was diagnosed in Mayo2004/European stage I, three patients in stages II, IIIA, IIIB each. Two patients (both stage IIIB) died due to complications associated with amyloid-related organ damage; 8 patients continue treatment. All patients achieved at least a very good partial hematologic response after the first cycle of Dara-CyBorD, 7 patients achieved complete response. In 5 cases, sustained organ response was achieved (cardiac in patients #1, #2, #5, #7; renal - #7, #9). Tolerability was acceptable, no serious adverse events were registered.
Conclusion
Daratumumab in combination with CyBorD has been demonstrated as a well-tolerated and effective therapy regimen for newly diagnosed AL amyloidosis. Rapid satisfactory hematologic responses were seen in all cases; sustained cardiac response was seen in select individuals regardless of initial disease stage.



Daratumumab in First-Line Combination Treatment of AL Amyloidosis:  Experience from Riga, Latvia PA162 (#359)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.